Document is current
Any future updates will be listed below
-
Authors
Mazzeo, Paolo https://orcid.org/0000-0001-6317-0216
Penir, Sarah Mae
Shumilov, Evgenii
Wolf, Sebastian
Häupl, Björn
Markus, Katharina
Shirneshan, Katayoon
Rittscher, Katharina
Brzuszkiewicz, Elzbieta
Aydilek, Enver https://orcid.org/0000-0003-1418-2725
Treiber, Hannes https://orcid.org/0000-0003-4436-5493
Oellerich, Thomas
Ganster, Christina https://orcid.org/0000-0002-7566-5985
Haase, Detlef
Koch, Raphael https://orcid.org/0000-0002-2018-5685
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70113602)
Hector Stiftung M2204
Deutsche Forschungsgemeinschaft (413501650)
Mildred-Scheel Nachwuchszentrum
- License Information
-
More Information
Article History
Received: 2 April 2025
Revised: 7 August 2025
Accepted: 28 August 2025
First Online: 19 September 2025
Competing interests
: DH: Advisory board, research support and honoraria by Bristol Myers Squibb and JAZZ. ES received honoraria from Amgen, BMS, Stemline, Sanofi, Incyte, Janssen, Takeda and JAZZ. RK received honoraria from Takeda, Janssen and Novartis. All other authors declare no conflict of interest.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local Ethics Committee of the University Medical Center Göttingen (application number 02-02-14). Informed consent was obtained from all patients.
